Robert C Penland

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 15

Top Venues

Diabetes, obesity & metabolism

Clinical pharmacokinetics

CPT: pharmacometrics & systems pharmacology

British journal of clinical pharmacology

AstraZeneca Pharmaceuticals LP

Duke University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

AstraZeneca Pharmaceuticals LP

United States

Director, Sr Clinical Pharmacometrician :: Quantitative Clinical Pharmacology

Novartis Institutes for BioMedical Research Inc

United States

Associate Director, Group Head :: Modeling & Simulation (Pharmacometrics)

Education History

Duke University

United States

PHD :: Biomedical Engineering

North Carolina State University

United States

MSC :: Nuclear Engineering

North Carolina State University

United States

BSC :: Nuclear Engineering

Publications

Robert C Penland, Magnus Åstrand, David W Boulton, Mats Någård
Population Pharmacodynamic Dose-Response Analysis of Serum Potassium Following Dosing with Sodium Zirconium Cyclosilicate. Clinical pharmacokinetics 63 (4) (2024)
Robert C Penland, Magnus Åstrand, David W Boulton, Mats Någård
Population Pharmacodynamic Dose-Response Analysis of Serum Potassium Following Dosing with Sodium Zirconium Cyclosilicate. Clinical pharmacokinetics 63 (4) (2024)
Robert C Penland, Magnus Åstrand, David W Boulton, Mats Någård
Population Pharmacodynamic Dose-Response Analysis of Serum Potassium Following Dosing with Sodium Zirconium Cyclosilicate. Clinical pharmacokinetics 63 (4) (2024)
Robert C Penland, Magnus Åstrand, David W Boulton, Mats Någård
Population Pharmacodynamic Dose-Response Analysis of Serum Potassium Following Dosing with Sodium Zirconium Cyclosilicate. Clinical pharmacokinetics 63 (4) (2024)
Robert C Penland, Magnus Åstrand, David W Boulton, Mats Någård
Population Pharmacodynamic Dose-Response Analysis of Serum Potassium Following Dosing with Sodium Zirconium Cyclosilicate. Clinical pharmacokinetics (2024)
Lindsay E Clegg, Lulu Chu, Mats Någård, David W Boulton, Robert C Penland
Potassium homeostasis and therapeutic intervention with sodium zirconium cyclosilicate: A model-informed drug development case study. CPT: pharmacometrics & systems pharmacology (2023)
Victor Sokolov, Tatiana Yakovleva, Leonid A Stolbov, Robert C Penland, David Boulton, Joanna Parkinson, Weifeng Tang
A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes. CPT: pharmacometrics & systems pharmacology (2023)
Johanna Melin, Joanna Parkinson, Bengt Hamrén, Robert C Penland, David W Boulton, Weifeng Tang
Dapagliflozin pharmacokinetics is similar between patients with heart failure with reduced ejection fraction and patients with type 2 diabetes mellitus. British journal of clinical pharmacology (2023)
Victor Sokolov, Tatiana Yakovleva, Leonid A Stolbov, Robert C Penland, David Boulton, Joanna Parkinson, Weifeng Tang
A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes. CPT: pharmacometrics & systems pharmacology (2023)
Lindsay E Clegg, Yankang Jing, Robert C Penland, David W Boulton, Adrian F Hernandez, Rury R Holman, Jiten Vora
Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials. Diabetes, obesity & metabolism 23 (5) (2021)
Millie Shah, Leonid A Stolbov, Tatiana Yakovleva, Weifeng Tang, Victor Sokolov, Robert C Penland, David W Boulton, Joanna Parkinson
A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes. Diabetes, obesity & metabolism 23 (4) (2021)
Annemarie B van der Aart-van der Beek, Lindsay E Clegg, Robert C Penland, David W Boulton, C David Sjöström, Robert J Mentz, Rury R Holman, Hiddo J Lambers Heerspink
Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial. Diabetes, obesity & metabolism 22 (12) (2020)
Nienke M A Idzerda, Lindsay E Clegg, Adrian F Hernandez, George L Bakris, Robert C Penland, David W Boulton, M Angelyn Bethel, Rury R Holman, Hiddo J Lambers Heerspink
Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. Diabetes, obesity & metabolism 22 (5) (2020)
Tatiana Yakovleva, Victor Sokolov, Lulu Chu, Weifeng Tang, Peter J Greasley, Helena Peilot Sjögren, Susanne Johansson, Kirill Peskov, Gabriel Helmlinger, David W Boulton, Robert C Penland
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. Diabetes, obesity & metabolism 21 (12) (2019)
Victor Sokolov, Tatiana Yakovleva, Shinya Ueda, Joanna Parkinson, David W Boulton, Robert C Penland, Weifeng Tang
Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus. Diabetes, obesity & metabolism 21 (4) (2018)

Robert C Penland.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Robert C Penland